Abstract: Objective:To investigate the clinical efficacy and safety of nimodiping on delayed cerebral vasospasm after traumatic subarachnoid hemorrhage(tSAH). Methods:Eighty patients with tSAH were randomly divided into nimodiping treatment group and control group. While the routine treatments of decreasing intracranial pressure,stopping bleeding,nutrition for nerve and so on,were used in two groups, the nimodiping was added through intravenous administration (1 mg/h) in treatment group. Two weeks later, nimodiping were continuously used through oral administration (30 mg tid) for 12-24 weeks. And then, the examination of color doppler were performed to observe hemodynamic changes of the middle cerebral artery at 24 hours,72 hours,the seventh,fourteenth day. Glasgow outcome scale after three months of the treatments was observed and analysed. Results:The levels of cerebral vasospasm and prognosis were significant difference between nimodiping treatment group and control group(P<0.05). Conclusions:Nimodiping can obviously prevent cerebral vasospasm and improve outcome of patient's after tSAH.